Ready-to-use ceftiofur hydrochloride injectable suspensions for bovine and swine respiratory disease are compounded at 50 mg ceftiofur equivalents per mL in an aqueous buffered vehicle. Terminal moist-heat sterilization at 121°C for 15 min is not compatible with the beta-lactam ring; the F0 value required for sterility assurance in porous loads typically exceeds the thermal exposure at which cephalosporin hydrolysis and polymeric impurity formation become unacceptable. Published quantitative degradation data for ceftiofur hydrochloride under saturated steam terminal cycles are limited. Aseptic processing is therefore used throughout. The vehicle is sterilized by filtration through 0.22 µm PVDF membrane filters and held at 20°C ±2°C; the API is sterilized separately by a validated method that must be confirmed for each crystalline lot, because residual moisture and endotoxin loads are lot-dependent. After aseptic addition, the suspension is milled under high shear in a jacketed rotor-stator mill. Process temperature is maintained at 20°C ±2°C; local rotor-stator heating above 60°C accelerates hydrolysis and must be avoided. The particle size target is a D90 below 25 µm. Excessive fines below 1 µm increase the dissolved fraction and the total surface area exposed to hydrolysis, while particles above 50 µm cause needle occlusion and dose non-uniformity. The dissolved fraction in the aqueous vehicle supplies immediate post-injection systemic exposure, whereas the suspended fraction controls depot release. A vehicle pH between 5.5 and 6.5 is maintained to reduce beta-lactam hydrolysis without fully suppressing the dissolved fraction; this pH window is the principal formulation conflict for ceftiofur hydrochloride ready-to-use suspensions. Final suspension viscosity is adjusted to 200–800 mPa·s at 20°C with a hydrophilic suspending agent to permit syringeability through an 18-gauge needle while retarding sedimentation. Sedimentation volume and resuspendability are measured according to a validated in-house method because no pharmacopoeial monograph for ceftiofur hydrochloride suspension exists; the acceptance criterion is based on the dose-uniformity requirement of the finished product. Sterility testing follows USP <71>, bacterial endotoxins follow USP <85>, subvisible particulate matter follows USP <788> Method 1 with limits for containers ≤100 mL of not more than 6000 particles ≥10 µm and 600 particles ≥25 µm per container, and visible particulate inspection follows USP <790>. Filling is performed in an ISO 5 unidirectional airflow zone under EU GMP Annex 1 aseptic conditions. Bromobutyl elastomeric closures with documented moisture barrier properties are selected because moisture ingress through stoppers during storage is a rate-limiting variable for hydrolytic degradation. Cleaning validation for beta-lactam cross-contamination is performed with surface swab limits derived from the health-based exposure limit of ceftiofur and is documented under 21 CFR 211.67.

Why Is Preservative-Free Aseptic Filling Used for Intramammary Ceftiofur Hydrochloride Gels?

In intramammary infusion products for lactating dairy cattle, ceftiofur hydrochloride is dispersed in a preservative-free aqueous gel and filled into single-dose syringes. A common dose strength is 125 mg ceftiofur equivalents per 10 mL syringe, although target-species approvals and mastitis severity dictate the labeled regimen. The formulation must avoid preservatives that would irritate the mammary epithelium or leave undesirable residues in milk; therefore, sterility is achieved by aseptic processing of pre-sterilized vehicle and API rather than by terminal preservation. Hydroxyethylcellulose, hypromellose, or carbomer gel vehicles provide shear-thinning behaviour so that the syringe contents can be expressed through a short intramammary cannula without excessive back-pressure. The aqueous phase is buffered to pH 5.5–6.5 to balance ceftiofur solubility and beta-lactam stability; excessive solubilization in the aqueous phase accelerates hydrolysis, while excessively low solubility reduces distribution into milk and mammary tissue fluid. Ceftiofur is a third-generation cephalosporin with stability against many plasmid-mediated beta-lactamases that hydrolyse earlier beta-lactams, but it is not a substitute for susceptibility testing against organisms expressing extended-spectrum beta-lactamases. Susceptibility breakpoints for veterinary pathogens are interpreted according to CLSI VET08 documents. Manufacturing scale challenges include gel viscosity variability caused by hydration time and temperature; the gel is hydrated for a fixed interval at 20–25°C under vacuum to remove entrained air before filling. The single-dose syringe components are selected for low leachables and low moisture transmission; polypropylene barrels and bromobutyl plunger stoppers are common. Finished units are inspected for visible particles according to USP <790>, and endotoxin is tested by USP <85>. Residue depletion in milk is not modified by formulation scale-up; any change to the vehicle or manufacturing site requires residue depletion studies under applicable veterinary residue guidance before marketing authorization is varied.

In oral tablet and capsule applications, ceftiofur hydrochloride is constrained by the same beta-lactam lability that governs injectable products. The drug is poorly absorbed from the monogastric stomach and undergoes acid-catalyzed hydrolysis; an enteric coating is required for any formulation intended to release ceftiofur in the small intestine. Direct compression is not the default process, because ceftiofur hydrochloride crystalline powder typically has low bulk density and poor flow; dry granulation by roller compaction is preferred over wet granulation to minimise hydrolytic exposure. Roller compaction at 3–6 MPa roll pressure produces granules with acceptable flow for tableting; if the granule fraction below 125 µm exceeds 30%, die-fill uniformity in a high-speed rotary press deteriorates. Compression force is set to achieve a tablet hardness of 6–10 kp on an instrumented rotary press; friability is controlled to NMT 1.0% according to USP <1216>. The tablet core is coated with a methacrylic acid copolymer dispersion, such as Eudragit L 30 D-55 or L 100-55, applied to a weight gain of 5–7% in a side-vented pan coater with inlet air temperature 30°C and product bed temperature 28°C. Enteric-coated tablets are tested by the delayed-release method in USP <711>: no drug release after 2 h in 0.1 N HCl, followed by not less than 80% release within 45 min in pH 6.8 phosphate buffer. For capsule filling, enteric-coated granules are filled into size 0 or size 1 hard gelatin or HPMC capsules; moisture content in the granules is controlled below 2.0% by Karl Fischer titration before filling. Published pharmacokinetic data for ceftiofur hydrochloride oral solid dosage forms in target veterinary species are limited; therefore, bioequivalence or bioavailability bridging studies are required before such a presentation can be registered rather than relying on compendial dissolution alone.

When Ceftiofur Hydrochloride Is Reconstituted as an Oral Granule, Moisture and Buffer pH Dictate Shelf Life

For oral granules and sachet forms, fluid-bed wet granulation is performed with an aqueous binder at an inlet air temperature of 40°C and a product bed temperature of 28°C; the residual moisture after drying is controlled below 2.0% by USP <921> Karl Fischer titration. Granules are filled into aluminium-lined sachets to limit oxygen and moisture ingress during storage. The granule formulation includes a phosphate or citrate buffer designed to maintain pH 5.5–6.5 after reconstitution in water; the buffer type and concentration are selected so that the finished suspension does not exceed acceptable daily sodium or potassium intake for the target species. Reconstituted suspension is stable for 24 h at 2–8°C; use beyond this interval is not recommended because aqueous ceftiofur hydrolysis proceeds even under refrigeration. Wet granulation is not without risk: water addition must be limited to the minimum required for binder activation, and any overwetting produces a granule mass that agglomerates in the fluid bed and extends drying time. These granules are intended for oral administration; however, published data for oral ceftiofur hydrochloride granules are limited, and available evidence indicates low oral bioavailability in monogastric species. Any proposed oral product therefore requires target-species pharmacokinetic and residue studies under the applicable regulatory pathway. The granule size distribution is controlled such that not less than 90% passes through a 1.0 mm sieve and not more than 15% is below 125 µm to reduce segregation during high-speed sachet filling.

Sterile Dry Powder Filling and Reconstitution for Injectable Depot Use

For injectable depot products distributed as dry powder, ceftiofur hydrochloride is aseptically crystallized or aseptically milled to a particle size compatible with rapid reconstitution; if the powder is too fine, it aggregates and floats on the diluent surface, and if it is too coarse, dissolution is slow. Dry powder is filled into Type I glass vials using a vacuum auger or dosator system under ISO 5 conditions; fill weight variation for a 1 g ceftiofur equivalent dose is controlled to ±5%. Residual moisture is controlled below 2.0% by USP <921>. Depyrogenation of vials and stoppers is performed by dry heat at 250°C for 30 min; beta-lactam powders can bind endotoxin, and the depyrogenation cycle must be validated for the entire component load. The powder is reconstituted with sterile water for injection or a buffered diluent at pH 5.5–6.5; if water alone yields a suspension rather than a clear solution, the diluent formulation must be registered with the product. The reconstituted product is held for no more than 24 h at 2–8°C because stability of aqueous ceftiofur is limited. Sterility testing follows USP <71>, bacterial endotoxins follow USP <85>, and particulate matter after reconstitution follows USP <788>. Terminal sterilization of the powder is not used; aseptic processing is mandatory.